Design of second generation phosphodiesterase 5 inhibitors

Current Topics in Medicinal Chemistry

Volumn 7, Issue 4, 2007, Pages 405-415

  Palmer, Michael J ^a   Bell, Andrew S ^a   Fox, David N A ^a   Brown, David G ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

4 Methyl pyridine 2 amine; Alkoxy pocket; cGMP; High throughput screening (HTS); Sildenafil

Indexed keywords

ALKOXYETHYL DERIVATIVE; CARBOXAMINOPYRIDINE DERIVATIVE; CYCLOALKOXYALKYL DERIVATIVE; METHOXYPYRIMIDINE DERIVATIVE; PHOSPHODIESTERASE; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE V; PHOSPHODIESTERASE V INHIBITOR; PHOSPHODIESTERASE VI; PHOSPHODIESTERASE X; PHOSPHODIESTERASE XI; PIPERAZINE DERIVATIVE; PIPERIDINE DERIVATIVE; PYRAZINE DERIVATIVE; PYRAZOLOPYRIMIDINE DERIVATIVE; PYRIDINE DERIVATIVE; PYRIDYLMETHYL DERIVATIVE; PYRIMIDINE DERIVATIVE; PYRROLIDINE DERIVATIVE; QUINAZOLINE DERIVATIVE; SILDENAFIL; TADALAFIL; TETRAHYDROPYRAN DERIVATIVE; UK 343664; UK 371800; UNCLASSIFIED DRUG; VARDENAFIL;

CHRONIC DRUG ADMINISTRATION; CRYSTAL STRUCTURE; DIABETES MELLITUS; DRUG APPROVAL; DRUG DESIGN; DRUG HALF LIFE; DRUG INDICATION; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG SELECTIVITY; ENZYME ACTIVE SITE; ENZYME INHIBITION; ERECTILE DYSFUNCTION; HEART PROTECTION; HIGH THROUGHPUT SCREENING; LIGAND BINDING; LIPOPHILICITY; MEMORY CONSOLIDATION; PHYSICAL CHEMISTRY; PROCESS OPTIMIZATION; PULMONARY HYPERTENSION; REVIEW; STRUCTURE ACTIVITY RELATION;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; MOLECULAR STRUCTURE; PHOSPHODIESTERASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33847653306     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802607779941288     Document Type: Review

References (28)

1. Beavo, J.A.; Brunton, L.L. Cyclic nucleotide research - still expanding after half a century. Nat. Rev. Mol. Cell Biol. 2002, 3, 710-718.
2. Burnett, A.L. Phosphodiesterase 5 mechanisms and Therapeutic Applications. Am. J. Cardiol. 2005, 96(12B), 29M-31M.
3. Rall, T.W.; Sutherland, E.W. Formation of a cyclic adenosine ribonucleotide by tissue particles. J. Biol. Chem. 1958, 232(76), 1065-1076.
4. Butcher, R.W.; Sutherland, E.W. Adenosine 3′,5′-phosphate in biological materials. I. Purification and properties of cyclic-3′,5′-nucleotide phosphodiesterase and use of this enzyme to characterize adenosine 3′,5′-phosphate in human urine. J. Biol. Chem. 1962, 237(50), 9021-9258.
5. Beavo, J.A. Cyclic Nucleotide Phosphodiesterases: Functional Implications of Multiple Isoforms. Physiol. Rev. 1995, 75(4), 725-748.
6. Corbin, J.D.; Francis, S.H. Cyclic GMP phosphodiesterase-5: target of sildenafil. J. Biol. Chem. 1999, 274(20), 13729-32.
7. Corbin, J.D.; Francis, S.H. Pharmacology of phosphodiesterase-5 inhibitors. Int. J. Clin. Practice 2002, 56(6), 453-459.
8. Sui, Z. Phosphodiestarase-5 inhibitors for male erectile dysfunction. Expert Opin. Ther. Patents 2003, 13(9), 1373-1388.
9. Rotella, D.P. Phosphodiesterase 5 Inhibitors: Current Status and Potential Applications. Nat. Rev. 2002, 1, 674-682.
10. Galie, N.; Ghofrani, H.A.; Torbicki, A.; Barst, R.J.; Rubin, L.J.; Badesch, D.; Fleming, T.; Parpia, T.; Burgess, G.; Branzi, A.; Grimminger, F.; Kurzyna, M.; Simonneau, G. Sildenafil Citrate therapy for Pulmonary arterial hypertension. N. Eng. J. Med. 2005, 353(20), 2148-2157.
11. Kukreja, R.C.; Ockaili, R.; Salloum, F.; Chang, Y.; Hawkins, J.; Das, A.; Xi, L. Cardioprotection with phosphodiesterase-5 inhibition - a novel preconditioning strategy. J. Mol. Cell. Cardiol. 2004, 36(2), 165-173.
12. Prickaerts, J.; Sik, A.; van Staveren, W.C.G.; Koopmans, G.; Steinbusch, H.W.M.; van der Staay, F.J.; de Vente, J.; Blokland, A. Phosphodiesterase type 5 inhibition improves early memory consolidation of object information. Neurochemistry Int. 2004, 45(6), 915-928.
13. Hood, S.; Kirby, M. PDE-5 inhibitors - a summary. Br. J. Diabet. Vas. Dis. 2004, 4(6), 383-386.
14. Eardley, I.; Cartledge, J. Tadalafil (Cialis) for men with erectile dysfunction. Int. J. Clin. Practice 2002, 56(4), 300-304.
15. Gupta, M.; Kovar, A.; Meibohm, B. The clinical pharmacokinetics of phosphodiesterase-5 inhibitors for erectile dysfunction. J. Clin. Pharmacol. 2005, 45(9), 987-1003.
16. Sommer, F. Potency and selectivity of Vardenafil: a phosphodiesterase type 5 inhibitor. Expert Opin. Drug Metabol. Toxicol. 2005, 1(2), 295-301.
17. Abel, S.; Beaumont, K.C.; Crespi, C.L.; Eve, M.D.; Fox, L.; Hyland, R.; Jones, B.C.; Muirhead, G.J.; Smith, D.A.; Venn, R.F.; Walker, D.K. Potential role for P-glycoprotein in the nonproportional pharmacokinetics of UK-343,664 in man. Xenobiotica 2001, 31(8), 665-676.
18. Bunnage, M.E.; Mathias, J.P.; Street, S.D.A.; Wood, A.; Beaumont, K.C.; Ballard, S.A. Design of potent and selective PDE5 inhibitors for treatment of MED. ACS Meeting 2002, 224th Boston(MEDI 2).
19. Zhang, K.Y.J.; Card, G.L.; Suzuki, Y.; Artis, D.R.; Fong, D.; Gillette, S.; Hsieh, D.; Neimann, J.; West, B.L.; Zhang, C.; Milburn, M.V.; Kim, S.-H.; Schlessinger, J.; Bollag, G. A Glutamine switch mechanism for nucleotide selectivity by phosphodiestereases. Mol. Cell 2004, 15(2), 279-286.
20. Brown, D.G.; Groom, C.R.; Hopkins, A.L.; Jenkins T.M.; Kamp, S.H.; O'Gara, M.M.; Ringrose, H.J.; Robinson, C.M.; Taylor, W.E. Crystal structures of human phosphodiesterase 5 and its ligand complex and their use in the design of site-directed mutants and design or screening of inhibitor compounds. 2004, WO 2004 097010 A1 20041111 AN 2004:965396 CAPLUS, 250.
21. Brown, D.G.; Groom, C.R.; Hopkins, A.L.; Jenkins T.M.; Kamp, S.H.; O'Gara, M.M.; Ringrose, H.J.; Robinson, C.M.; Taylor, W.E. Crystal structures of human phosphodiesterase 5 and its ligand complex and their use in the design of site-directed mutants and design or screening of inhibitor compounds. 2003, WO 2003 038080 A1 20030508 CAN 138:364748 AN 2003:356596 CAPLUS, 442.
22. Stamford, A.W. Phosphodiesterase 5 Inhibitors. Ann. Reports Med. Chem. 2002, 37, 53-64.
23. Hopkins, A.L.; Groom, C.R.; Alex, A. Ligand efficiency: a useful metric for lead selection. Drug Discov. Today 2004, 9(10), 430-431.
24. Kuntz, I.D.; Chen, K.; Sharp, K.A.; Kollman, P.A. The maximal affinity of ligands Proc. Nat. Acad. Sci USA 1999, 96(18), 9997-10002.
25. Bell, A.S.; Brown, D.G.; Fox, D.N.A.; Marsh, I.R.; Morrell, A.I.; Palmer, M.J.; Winslow, C.A. Preparation of 5,7-diaminopyrazolo [4,3-d]pyrimidines as selective PDE5 inhibitors useful in the treatment of hypertension. WO 2004096810 2004.
26. Pandit, J. Crystal Structure of 3′, 5′-CyclicNucleotide Phosphodiesterase (PDE10A) and Uses Thereof Pfizer, Inc.: US 2005/ 0202550 2005.
27. Manallack, D.T.; Hughes, R.A.; Thompson, P.E. The next generation of Phosphodiesterase Inhibitors: Structural Clues to ligand and Substrate Selectivity of Phosphodiesterases. J. Med. Chem. 2005, 48(10), 3449-3462.
28. Bell, A.S.; Brown, D.G.; Bull, D.; Fox, D.N.A.; Marsh, I.R.; Morrell, A.I.; Palmer, M.J.; Winslow, C.A. Preparation of pyrazolopyrimidines as cyclic guanylate monophosphate-specific phosphodiesterase type 5 inhibitors. WO 2005/049617 2005.